Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report) is set to announce its earnings results before the market opens on Tuesday, May 14th.
40 minutes ago

Fennec's Pedmarqsi/Pedmark is the only approved therapy to treat cisplatin-induced hearing loss in paediatric cancer patients.
1 month ago

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. With the latest financial year loss of US$24m and a trailing-twelve-month...
1 month ago

Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price · Summary · Fennec Pharmaceuticals – Revenue Guidance and EU...
2 months ago

Fennec Pharmaceuticals (NASDAQ:FENC) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports.
3 days ago

Fennec signs commercialization deal for Pedmarqsi with Norgine ... US speciality drugmaker Fennec Pharmaceuticals (Nasdaq: FENC) and Norgine today...
1 month ago

A drugmaker in Research Triangle Park has landed more than $40 million in a licensing deal and could earn much more as it pursues...
1 month ago

Fennec Pharmaceuticals (TSE:FRX) has released an update. Fennec Pharmaceuticals has entered into an exclusive agreement with Norgine to commercialize...
1 month ago

(NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company...
1 month ago

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call Transcript November 6, 2023 Fennec Pharmaceuticals Inc. beats earnings...
6 months ago